335TiP Open-label, multinational, multicenter, phase IIIb/IV study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer (HER2+ BC): DESTINY-Breast12
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI